Lilly’s Prevail, Doudna’s Scribe partner on genetic treatments for neuro diseasesR&D, TherapeuticsThe $75 million deal will leverage Scribe’s CRISPR technologies to develop gene therapies for neurological and neuromuscular disorders. Scribe previously struck deals with Biogen and Sanofi. Read more May 17, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpaceCRISPR4-10-2023.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-05-17 09:36:482023-05-17 09:37:40Lilly’s Prevail, Doudna’s Scribe partner on genetic treatments for neuro diseases
